StockNews.com began coverage on shares of Applied DNA Sciences (NASDAQ:APDN – Free Report) in a research note issued to investors on Friday. The firm issued a hold rating on the technology company’s stock.
Separately, HC Wainwright cut their price target on Applied DNA Sciences from $4.00 to $2.00 and set a buy rating on the stock in a research report on Friday, December 8th.
Applied DNA Sciences Stock Down 7.2 %
Applied DNA Sciences (NASDAQ:APDN – Get Free Report) last announced its earnings results on Thursday, December 7th. The technology company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. The company had revenue of $0.78 million during the quarter, compared to analysts’ expectations of $1.60 million. Applied DNA Sciences had a negative return on equity of 159.93% and a negative net margin of 80.14%. On average, equities analysts anticipate that Applied DNA Sciences will post -0.87 earnings per share for the current year.
Institutional Investors Weigh In On Applied DNA Sciences
Institutional investors and hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its stake in Applied DNA Sciences by 53.0% during the first quarter. Dimensional Fund Advisors LP now owns 65,916 shares of the technology company’s stock valued at $141,000 after buying an additional 22,843 shares in the last quarter. Atria Wealth Solutions Inc. acquired a new stake in Applied DNA Sciences during the first quarter valued at approximately $67,000. State Street Corp raised its position in shares of Applied DNA Sciences by 53.6% during the 1st quarter. State Street Corp now owns 26,977 shares of the technology company’s stock worth $58,000 after purchasing an additional 9,416 shares during the period. Virtu Financial LLC acquired a new stake in shares of Applied DNA Sciences during the 1st quarter worth approximately $49,000. Finally, Prudential Financial Inc. acquired a new stake in shares of Applied DNA Sciences during the 2nd quarter worth approximately $34,000. Hedge funds and other institutional investors own 17.34% of the company’s stock.
Applied DNA Sciences Company Profile
Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.
- Five stocks we like better than Applied DNA Sciences
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- 3 attractive stocks that insiders are buying
- EV Stocks and How to Profit from Them
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Applied DNA Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied DNA Sciences and related companies with MarketBeat.com's FREE daily email newsletter.